Skip to content

EARLY FOLLICULAR PHASE vs LUTHEAL PHASE OVARIAN STIMULATION IN BOLOGNA CRITERIA IVF/ICSI CYCLES: A RANDOMIZED COMPARATIVE SINGLE CENTER TRIAL. LUTEAL TRIAL

EARLY FOLLICULAR PHASE vs LUTHEAL PHASE OVARIAN STIMULATION IN BOLOGNA CRITERIA IVF/ICSI CYCLES: A RANDOMIZED COMPARATIVE SINGLE CENTER TRIAL. LUTEAL TRIAL - LUTEAL TRIAL

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2015-003856-31-ES
Enrollment
Unknown
Registered
2015-10-30
Start date
2015-12-04
Completion date
Unknown
Last updated
2015-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with diagnosis of low response (Bologna criteria) and who perform ovarian stimulation for accumulation of vitrified oocytes. MedDRA version: 18.1 Level: LLT Classification code 10016398 Term: Female infertility System Organ Class: 100000004872

Interventions

Trade Name: Pergoveris 150 UI/75 UI polvo y disolvente para solución inyectable Pharmaceutical Form: Solution for injection INN or Proposed INN: FOLLITROPIN ALFA Current Sponsor code: G03GA30 Other de

Sponsors

INSTITUTO BERNABEU
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: . Patient Bologna meets the criteria to be diagnosed as low responder. 2. Age under 41 years 3. Regular menstrual cycles between 21 and 35 days. 4. indication of in vitro fertilization 5. Indication of start stimulation with 300 IU of FSH 6. Presence of both ovaries 7. Ability to participate and comply with the study protocol 8. Having signed the written consent form Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 60 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: 1. Presence of follicles larger than 10 mm in the randomization visit 2. Endometriosis III / IV 3. Concomitant uterine pathology: adenomyosis, submucosal myomas, Asherman's syndrome ... 4. Concurrent participation in another study

Design outcomes

Primary

MeasureTime frame
Main Objective: To study the efficacy of ovarian stimulation in luteal phase compared to ovarian stimulation in follicular phase in women with low responder criteria.;Secondary Objective: -Assess whether there are differences between the two groups in terms of duration of stimulation -Study of the differences between the two groups in terms of consumption of gonadotropins and cost of treatment -Assess whether there are differences between the two groups in the rate of cancellation of the stimulation cycle -Assess whether there are differences between the two groups in the rate of oocytes in metaphase II stage -Assess whether there are differences between the two groups in the rate of survival in the thawing and fertilization rate after microinjection.;Primary end point(s): Number of oocytes in metaphase II obtained;Timepoint(s) of evaluation of this end point: End of controlled ovarian hyperstimulation and oocyte maturation

Secondary

MeasureTime frame
Secondary end point(s): - Number of oocytes cumulus complexes - Duration of stimulation (days) - Cycle cancellation rate - The LH levels following administration of agonist for final oocyte maturation day - Fertilization rate;Timepoint(s) of evaluation of this end point: End of controlled ovarian hyperstimulation and oocyte maturation

Countries

Spain

Contacts

Public ContactMEDICINA REPRODUCTIVA

INSTITUTO BERNABEU

jllacer@institutobernabeu.com0034965154000

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026